Matrixx Initiatives, Inc. v. Siracusano
GPTKB entity
Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:legal_case
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Rule_10b-5
|
| gptkbp:court |
gptkb:United_States_Supreme_Court
|
| gptkbp:decided_by |
March 22, 2011
|
| https://www.w3.org/2000/01/rdf-schema#label |
Matrixx Initiatives, Inc. v. Siracusano
|
| gptkbp:is_cited_in |
563 U. S. 27
|
| gptkbp:is_involved_in |
gptkb:Matrixx_Initiatives,_Inc.
Siracusano |
| gptkbp:legal_issue |
securities fraud
|
| gptkbp:outcome |
ruled in favor of Matrixx Initiatives
|
| gptkbp:precedent |
established standards for materiality in securities fraud cases
|
| gptkbp:significance |
impact on disclosure requirements for pharmaceutical companies
|